No Data
Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $51 to $75
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
Avidity Biosciences Is Maintained at Buy by Chardan Capital
Avidity Biosciences Pursues Potential Accelerated Approval Path With Initiation Of Biomarker Cohort In FORTITUDE Trial For Delpacibart Braxlosiran In People Living With Facioscapulohumeral Muscular Dystrophy
Express News | Avidity Biosciences: Enrollment in Del-Brax Biomarker Cohort Expected to Be Completed in 1H 2025
No Data
No Data